Retrospective drug utilization review of meropenem and role of infectious disease pharmacist in specialized cancer care hospital

Abstract

Objectives

Carbapenem antimicrobials are considered for the treatment of serious bacterial infections. The objective of this study was to review the use of meropenem in cancer patients and to evaluate the impact of clinical pharmacist's intervention in this practice to reduce possible risks associated with use of meropenem.

Methods

This retrospective study was conducted among 100 patients who received meropenem at hospital. A structured questionnaire was used to collect data. Descriptive statistics was used to analyze the collected data.

Results

A total of 100 patients were included in this retrospective study with aim to review rationality and possible side effects associated with meropenem use in our study population. It was revealed that meropenem used was associated with rise in bilirubin in many of our study patients. Pharmacist were found to be instrumental in placing timely interventions for either de-escalation or switch of meropenem to imipenem/cilastatin to reduce that risk. Interventions were accepted by physicians in most of the cases.

Conclusion

De-escalation and switching were performed in accordance with pharmacist recommendations in more than half of study population with empirically started/ study population in which meropenem was used.

Keywords

Antimicrobial resistance drug utilization evaluation meropenem deescalation pharmacists

Get full access to this article

View all access options for this article.

References

Erbay

Bodur

Akıncı

, et al. Evaluation of antibiotic use in intensive care units of a tertiary care hospital in Turkey. J Hosp Infect 2005; 59: 53–61.

Saleem

Hassali

Godman

, et al. Point prevalence surveys of antimicrobial use: a systematic review and the implications. Expert Rev Anti-Infect Ther 2020; 18: 897–910.

Saleem

Hassali

Versporten

, et al. A multicenter point prevalence survey of antibiotic use in punjab, Pakistan: findings and implications. Expert Rev Anti-Infect Ther 2019; 17: 285–293.

Mahini

Hayatshahi

Torkamandi

, et al. Carbapenem utilization in critically Ill patients. J Pharm Care 2013; 1: 141–144.

Saleem

Saeed

Hassali

, et al. Pattern of inappropriate antibiotic use among hospitalized patients in Pakistan: a longitudinal surveillance and implications. Antimicrob Resist Infect Control 2019; 8: 1–7.

Kollef

Micek

Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 2005; 33: 1845–1853.

Aminov

Mackie

. Evolution and ecology of antibiotic resistance genes. FEMS Microbiol Lett 2007; 271: 147–161.

Iredell

Brown

Tagg

. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. Br Med J 2016; 352: h6420.

Frieden

. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, US Department of Health and Human Services 2013; 23: 11–28.

10.

Spellberg

Guidos

Gilbert

, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the infectious diseases society of america. Clin Infect Dis 2008; 46: 155–164.

11.

Leung

Weil

Raviglione

, et al. World health organization world health Day antimicrobial resistance technical working G. The WHO policy package to combat antimicrobial resistance. Bull World Health Organ 2011; 89: 390–392.

12.

Zaidi

Awasthi

deSilva

. Burden of infectious diseases in south Asia. Br Med J 2004; 328: 811–815.

13.

Khan

Hafeez

Ikram

. Situation analysis report on antimicrobial resistance in Pakistan-findings and recommendations for antibiotic use and resistance. Internet] The Global Antibiotic Resistance Partnership (GARP), Pakistan[cited 2018 Mar 19] Available from: https://www cddep org/publications/garp-pakistan-situation-analysis 2018 (accessed 15 August 2021).

14.

Saleem

Saeed

Ahmad

, et al. Antibiotic self-prescribing trends, experiences and attitudes in upper respiratory tract infection among pharmacy and non-pharmacy students: a study from lahore. PloS one 2016; 11: e0149929.

15.

Kumarasamy

Toleman

Walsh

, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597–602.

16.

Saleem

Hassali

. Travellers take heed: outbreak of extensively drug resistant (XDR) typhoid fever in Pakistan and a warning from the US CDC. Travel Med Infect Dis 2019; 27: 127.

17.

WHO. Global action plan on antimicrobial resistance. WHO Report. 2015.

18.

Tamma

Cosgrove

. Antimicrobial stewardship. Infect Dis Clin 2011; 25: 245–260.

19.

Fishman

America

. Policy statement on antimicrobial stewardship by the society for healthcare epidemiology of america (SHEA), the infectious diseases society of america (IDSA), and the pediatric infectious diseases society (PIDS). Infect Control Hosp Epidemiol 2012; 33: 322–327.

20.

Barlam

Cosgrove

Abbo

, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of america and the society for healthcare epidemiology of america. Clin Infect Dis 2016; 62: e51–e77.

21.

Dellit

Owens

McGowan

, et al. Infectious diseases society of america and the society for healthcare epidemiology of america guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159–177.

22.

Masterton

. Antibiotic de-escalation. Crit Care Clin 2011; 27: 149–162.

23.

Niederman

. De-escalation therapy in ventilator-associated pneumonia. Curr Opin Crit Care 2006; 12: 452–457.

24.

Dellinger

Levy

Carlet

, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17–60.

25.

Leone

Bechis

Baumstarck

, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014; 40: 1399–1408.

26.

la Martire

Robin

Oubaya

, et al. De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome. Eur J Clin. Microbiol Infect Dis 2018; 37: 1931–1940.

27.

Katsios

Burry

Nelson

, et al. An antimicrobial stewardship program improves antimicrobial treatment by culture site and the quality of antimicrobial prescribing in critically ill patients. Crit Care 2012; 16: 1–9.

28.

Fujibayashi

Niwa

Takeichi

, et al. Clinical impact of a prospective audit with intervention and feedback without carbapenem restriction in patients receiving carbapenem injection. Int J Clin pract 2019; 73: e13262.

29.

Weiss

Zahar

J-R

Lesprit

, et al. Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams. Clin Microbiol Infect 2015; 21: 649. e1-. e10.

30.

Tabah

Bassetti

Kollef

, et al. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European society of intensive care medicine (ESICM) and European society of clinical microbiology and infectious diseases (ESCMID) critically Ill patients study group (ESGCIP). Intensive Care Med 2020; 46: 245–265.

31.

Morel

Casoetto

Jospé

, et al. De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care 2010; 14: 1–7.

32.

MacDougall

Polk

. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005; 18: 638–656.

33.

Tonna

Stewart

West

, et al. Antimicrobial optimisation in secondary care: the pharmacist as part of a multidisciplinary antimicrobial programme—a literature review. Int J Antimicrob Agents 2008; 31: 511–517.

34.

Rho

Morcos

, et al. Evaluation of dedicated infectious diseases pharmacists on antimicrobial stewardship teams. Am J Health Syst Pharm 2014; 71: 1019–1028.

35.

Wickens

Farrell

Ashiru-Oredope

, et al. The increasing role of pharmacists in antimicrobial stewardship in English hospitals. J Antimicrob Chemother 2013; 68: 2675–2681.

36.

Essack

Bell

Shephard

. Community pharmacists—leaders for antibiotic stewardship in respiratory tract infection. J Clin Pharm Ther 2018; 43: 302–307.

37.

Ghiga

Lundborg

. ‘Struggling to be a defender of health’–a qualitative study on the pharmacists’ perceptions of their role in antibiotic consumption and antibiotic resistance in Romania. J Pharm Policy Pract 2016; 9: 1–10.

38.

De Waele

Ravyts

Depuydt

, et al.

De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality?

J Crit Care 2010; 25: 641–646.

39.

Duchêne

Montassier

Boutoille

, et al.

Why is antimicrobial de-escalation under-prescribed for urinary tract infections?

Infection 2013; 41: 211–214.

40.

Hawkey

Livermore

. Carbapenem antibiotics for serious infections. Br Med J 2012; 344: e3236.

41.

Hornik

Herring

Benjamin

Jr , et al. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J 2013; 32: 748.

42.

Cunha

. Meropenem in elderly and renally impaired patients. Int J Antimicrob Agents 1998; 10: 107–117.

43.

Sieger

Berman

Geckler

, et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Crit Care Med 1997; 25: 1663–1670.

44.

Sanhoury

Eldalo

. Evaluation of meropenem utilization in intensive care unit in Sudan. Int J Clin Pharmacol Pharmacother 2016; 1: 2.

45.

Bradley

Faulkner

Klugman

. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr Infect Dis J 1996; 15: 749–757.

46.

Cohen-Wolkowiez

Poindexter

Bidegain

, et al. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis 2012; 55: 1495–1502.

47.

Zhanel

Simor

Vercaigne

, et al. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Infect Dis 1998; 9: 215–228.

48.

Garau

Bassetti

. Role of pharmacists in antimicrobial stewardship programmes. Int J Clin Pharm 2018; 40: 948–952.

49.

Cunha

. Antimicrobial stewardship programs: principles and practice. Med Clin 2018; 102: 797–803.

50.

Gilchrist

Wade

Ashiru-Oredope

, et al. Antimicrobial stewardship from policy to practice: experiences from UK antimicrobial pharmacists. Infect Dis Ther 2015; 4: 51–64.

51.

Magedanz

Silliprandi

Dos Santos

. Impact of the pharmacist on a multidisciplinary team in an antimicrobial stewardship program: a quasi-experimental study. Int J Clin Pharm 2012; 34: 290–294.

52.

Barlam

Cosgrove

Abbo

, et al. Executive summary: implementing an antibiotic stewardship program: guidelines by the infectious diseases society of america and the society for healthcare epidemiology of america. Clin Infect Dis 2016; 62: 1197–1202.

53.

Davey

Peden

Brown

, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients (updated protocol). Cochrane Database Syst Rev 2014; 8: CD011236.